top of page

Neuland CDMO Website

Frame 2121457967 (1).png

Architecting a Global B2B CDMO Portal for Complex Small Molecules & Peptides

Domain

Bio-Pharma CDMO, Complex API & Peptide Manufacturing, B2B Enterprise Tech

Role

Lead Product Designer & UX Consultant (Full-Lifecycle Design Ownership)

Design Tools

image 26.png

Figma

image 52 (1).png

Claude

image 14.png

Clevertap

image 13.png

Useberry

Core Impact

  • Accelerated qualified inbound scientific consultation requests by +42% via context-aware lead forms.

  • Compressed technical capability and peptide modality lookup time from 5 minutes to < 45 seconds.

  • Increased high-value "Proven in Practice" case study downloads and engagement by +55%.

  • Reduced frontend implementation friction by 40% through the Neuland Enterprise Design Tokens framework.

MacBook Air (15 inch).png

Strategic Overview

Context

Neuland Laboratories is a leading global Contract Development and Manufacturing Organization (CDMO) with over 40 years of API expertise, supporting 150+ pharmaceutical clients across 30+ countries. Operating 3 cGMP manufacturing facilities and managing 18+ commercial CDMO programs, Neuland specializes in complex small molecules and advanced peptide synthesis (SPPS, LPPS, and hybrid technologies) across the full drug lifecycle—from early R&D to commercial scale-up.

The Baseline Problem

Neuland’s legacy digital platform struggled to communicate its advanced technical capabilities to global biotech R&D directors and pharma procurement heads:

  • Friction-Heavy Consultation Funnel: Scientific consultation CTAs were buried inside generic contact pages, resulting in a 60%+ drop-off rate among high-intent procurement leads.

  • Fragmented Modality Architecture: Technical specs for complex peptides (Solid-Phase vs. Liquid-Phase Synthesis) and small molecules were obscured by dense text blocks without clear lifecycle mapping.

  • Visual Inconsistency: The absence of a standardized enterprise design token system weakened Neuland’s visual authority against top-tier global CDMO competitors.

Strategic Objectives & Product Vision

Product Objectives

  • Accelerate Lead Velocity & Consultation Funnel (Lead Capture Goal): Compress technical capability discovery and scientific inquiry scheduling to under 45 seconds using inline, context-aware lead capture forms ("Start a Scientific Conversation").

  • Establish Technical Authority & De-Risking (Trust & Conversion Goal): Present synthesis modalities, regulatory compliance credentials (USFDA/cGMP), and supply chain de-risking frameworks clearly across all stages of drug development.

  • Architect a Scalable Enterprise Design System (Brand Equity Goal): Build a unified, AA/AAA WCAG-compliant design token system (Instrument Sans display, Inter body, Primary Dark Green #034632, and high-visibility Orange #FF823C CTAs) to elevate Neuland’s global market presence.

Group 10 (1).png

User Personas & Behavioral Psychology

Primary Personas

  • Dr. Elena, VP of Peptide Development (Client-Side R&D)
    Profile: 46-year-old biopharma VP managing synthetic peptide pipelines for a mid-sized US biotech firm.
    Mindset & Friction: Technical, cautious, and highly risk-averse. Anxious about yield purity, SPPS vs. LPPS scalability, and regulatory filing delays. Frustrated when CDMO websites hide technical specs behind mandatory sales calls.

  • Marcus, Global Bio-Pharma Procurement Director (B2B Buyer)
    Profile: 41-year-old commercial procurement leader sourcing API manufacturing partners for Phase II/III clinical trials.
    Mindset & Friction: Speed- and security-driven. Evaluates CDMOs on cGMP compliance, USFDA inspection history, and supply continuity. Needs quick access to case studies and direct consultation booking.

Group 11.png

Applied UX Psychology Frameworks

  • Hick's Law & Progressive Disclosure (Modality Discovery):
    Problem: R&D directors were overwhelmed by unorganized chemical documentation across small molecules and peptides.
    UX Solution: Structured technical capabilities into tabbed modality cards (SPPS, LPPS, Hybrid Synthesis) with clear sub-headings, reducing decision fatigue and enabling 45-second technical validation.

  • Authority Bias & Prevention Architecture (De-Risking Framework):
    Problem: Procurement buyers hesitated to submit RFPs without verified proof of regulatory compliance and manufacturing scale.
    UX Solution: Placed a persistent metric bar (40+ Years API Expertise, 3 cGMP Sites, 150+ Global Clients, 18+ Commercial Programs) at the top of key pages alongside explicit de-risk cards (Development, Regulatory, Supply Risk).

  • Goal-Gradient Effect & Fitts's Law (Scientific Consultations):
    Problem: High lead drop-offs occurred when users were redirected to generic multi-step contact pages.
    UX Solution: Embedded context-aware inline forms ("Start a Scientific Conversation") directly within capability pages, utilizing oversized Orange (#FF823C) touch targets to minimize physical and cognitive effort.

Information Architecture (IA)

The platform Information Architecture is organized into a 4-Module CDMO Pipeline, guiding visitors smoothly from high-level capability discovery to technical de-risking, case study evaluation, and direct scientific consultation.

Task-Oriented Navigation & Prioritization
 

  • CAPABILITY KRA (Modality & Synthesis Engine): Global Navigation ➔ "CDMO Services". Dedicated landing hubs for Small Molecules and Peptides, breaking down synthesis methods (SPPS, LPPS, Hybrid), supported modalities, and analytical validation.

  • LIFECYCLE KRA (Molecule Scale-Up & De-Risking): Sub-Header Bar ➔ "Drug Lifecycle Support". Interactive 3-stage progression (Early R&D ➔ Clinical Scale-Up ➔ Commercial cGMP Supply) paired with explicit Development, Regulatory, and Supply de-risking cards.

  • CONSULTATION KRA (Inline Scientific Inquiry Funnel): Action Panel ➔ "Start a Scientific Conversation". Contextual inline lead capture forms with dynamic dropdowns (Peptides, Small Molecules, Generic APIs) embedded directly on capability pages.

  • TRUST KRA (Proven in Practice & ESG Portal): Section Block ➔ "Why Choose Neuland". Showcases real-world case studies (e.g., Scaling a complex API from early R&D to commercial supply), global plant locations, and ESG sustainability commitments.

Group 12 (1).png

Wireframing & Low-Fidelity Iterations

Lead Capture Form Accessibility Pivot

  • Initial Concept: A single, centralized "Contact Us" link in the top navigation leading to a 7-field generic inquiry form.

  • Testing Friction: High abandonment rate (62%). R&D directors researching specific modalities (e.g., Peptides LPPS) refused to break their reading flow to navigate to a separate contact page.

  • The UX Pivot: Embedded Contextual Inline Lead Cards ("Start a Scientific Conversation" / "Speak to one of our experts") directly at the bottom of capability pages, pre-selecting the relevant service topic.

  • UX Rationale: Applied the Goal-Gradient Effect and Fitts's Law, capturing leads at peak intent and cutting form submission effort in half.

Technical Synthesis Presentation Pivot

  • Initial Concept: Long, unstructured text paragraphs describing chemical capabilities and cGMP plant details.

  • Testing Friction: R&D evaluators spent up to 5 minutes digging for specific synthesis limits (e.g., Solid Phase vs. Liquid Phase peptide capabilities).

  • The UX Pivot: Replaced text blocks with Structured Modality Cards (Solid-phase synthesis SPPS, Liquid-phase synthesis LPPS, Hybrid technology) paired with concise bulleted feature lists and clear visual icons.

  • UX Rationale: Leveraged Chunking & Visual Hierarchy, allowing scientific buyers to evaluate technical compatibility in under 45 seconds.

High-Fidelity UI & Core Feature Breakdown

Interactive Modality & Peptide Synthesis Hub

MacBook Air (15 inch) 1.png
Group 58481 1.png

  • Structured Modality Grid: Displays Solid Phase (SPPS), Liquid Phase (LPPS), and Hybrid peptide technologies in scannable cards, highlighting supported modalities (Linear/Cyclic, Modified, Peptidomimetics) alongside scale-up metrics.

  • Persistent Credibility Banner: A high-visibility trust bar (40+ Years API Expertise, 3 cGMP Sites, 150+ Global Clients, 18+ Commercial Programs) anchored beneath hero sections to reinforce market leadership.

Drug Lifecycle & De-Risking Framework

  • 3-Stage Lifecycle Mapping: Guides formulators across Early Development & R&D, Process Optimization & Scale-Up, and Clinical to Commercial Manufacturing.

  • Dedicated Risk Mitigation Cards: Categorizes de-risking capabilities into three clear pillars: Development Risk (analytical & process development), Regulatory Risk (USFDA/EMA inspection history), and Supply Risk (dual-site manufacturing & raw material security).

Contextual Scientific Lead Engine & Design System Integration

  • High-Contrast Consultation Cards: High-visibility lead capture blocks utilizing Dark Green (#034632) and Orange (#FF823C) primary action buttons with reCAPTCHA validation and inline privacy policy consent.

  • Proven in Practice Case Studies: Highlighting real-world scale-up successes (e.g., Process development & scale-up of a 20-AA peptide) with 1-click PDF download triggers and related news updates.

Design System & Scalability

To guarantee visual authority and accelerate frontend delivery across desktop and mobile screens, I architected the Neuland Enterprise Design Tokens (NEDT) framework

  • Typography Tokens: Instrument Sans (Display 52px/44px, Bold 700) for authoritative headers, paired with Inter (Body 18px/16px/14px, Regular/Medium) for high-density scientific text legibility.

  • Color Palette Tokens: Primary Dark Green (#034632), High-Visibility Orange (#FF823C) for primary CTAs, Light Blue (#1EB4F0) for interactive accents, Classic Green (#01D264), and Light Backgrounds (#F1F5F5).

  • Component Library: Standardized UI components including modality feature cards, de-risking badge grids, inline consultation forms, and accordion FAQ panels.

  • %.

Frame 2121458933.png

Real Improvements & Measurable Impact

Quantifiable Business Outcomes & Operational ROI

By transforming Neuland's digital presence from a static marketing portal into an interactive CDMO capability engine, the redesigned platform generated validated gains across lead velocity, discovery speed, and buyer trust:
 

  • Scientific Lead Generation: Accelerated qualified inbound consultation inquiries by +42% via context-aware inline forms.
     

  • Modality Discovery Speed: Compressed technical capability and synthesis spec lookup time from 5 minutes to < 45 seconds.
     

  • Case Study Engagement: Boosted views and PDF downloads of "Proven in Practice" scale-up case studies by +55%.
     

  • Buyer Trust & Credibility: Improved institutional buyer evaluation scores by +38% through visible cGMP and USFDA compliance proof.
     

  • Design Handoff Efficiency: Reduced frontend development sprint timelines by 40% using the Neuland Enterprise Design Tokens framework.

bottom of page